EXPERIMENTAL DAY
9.20 – 9.30 | Welcome YIN representatives
9.30 – 9.45 | Tumour progression shows decrease in PD-L1 expression in matched metastases/primary uveal melanomas | Rob Verdijk
9.45 – 10.00 | Uveal Melanoma cells suppress the antitumor response of Natural Killer lymphocytes | Alessandra Loda
10.15 – 10.30 | Immune Landscape of Uveal Melanoma | Antonia Joussen
11.00 – 11.15 | Validation of the geometric eye model used in ocular proton therapy planning | Jan-Willem Beenakker
11.15 – 11.30 | Tracking Treatment Effects in Radiation Macular Edema using OCT Biomarkers: an Artificial Intelligence Approach | Edoardo Midena
11.30 – 11.45 | Quantitative perfusion-weighted magnetic resonance imaging for intraocular lesions | Iris Mulder
11.45 – 12.00 | Results of training the neural network in detecting small choroidal melanocytic lesions and associated subretinal fluid on OCT scans | Emilia Zwolińska
12.15 – 12.30 | Development of a validation setup for fusing fundus photographs and MRI | Corné Haasjes
12.30 – 12.45 | Impact of Anterior Segment Swept-Source Optical Coherence Tomography for the Diagnosis of Conjunctival Tumors | Sasha Nahon-Esteve
12.45 – 13.00 | Estimating uveal melanoma volume with ellipsoid tumour models | Lisa Klaassen
14.45 – 15.00 | The p53 isoforms as modifiers of p53 tumor suppressor ability in uveal melanoma | Yari Ciribilli
15.00 – 15.15 | Analysis of proliferation in uveal melanoma eyes after secondary enucleation for indications other than clinical relapse | Julien Schaller
15.15 – 15.30 | Generation of monosomy 3 in the proliferating uveal melanoma cells under hyperglycemia | Aysegül Tura
15.30 – 15.45 | Differential Responses of Retinal Cells and Uveal Melanoma Organoids to Proton Irradiation | Susanne Wolf
15.45 – 16.00 | Uveal Melanoma: Bridging Research with Effective, Reliable, and Immunocompetent Mouse Models | Zeinab El Rashed
16.30 – 16.45 | Subclass dependent biomarkers involved in uveal melanoma progression, cell plasticity and metastatic risk | Erwin Brosens
16.45 – 16.50 | Heterogeneity of p53 functionality in uveal melanoma: do p53 isoforms have a role | Samuele Brugnara
16.50 – 16.55 | Limbal stem cell transplantation for severe limbal stem cell deficiency in ocular oncology | Ekaterina Sokolenko
16.55 – 17.00 | Targeting Epigenetic and Metabolic Pathways in Uveal Melanoma | Valentina Rigo
OCULAR MELANOMA DAY
8.30 – 8.45 | Retino-invasive uveal melanoma: a spatial transcriptomic study | Alexandre Moulin
8.45 – 9.00 | Tumor-intrinsic effect of PIK3CD in uveal melanoma and implication in the clinical evaluation of the PI3Kd inhibitor Roginolisib | Michael Lahn
9.00 – 9.15 | Somatic genomic prognostication of uveal melanoma: long-term study on metastatic risk and survival | Anna Giulia Di Dario
9.15 – 9.30 | Prognostic Significance of Tumor Histological Type, BAP1 Gene Expression, and Tumor Environment (TILs/TAMs) in Uveal Melanoma: What is More Important? | Elena Grishina
9.30 – 9.45 | Proteomic Dynamics of Aqueous Humor in Uveal Melanoma: a Longitudinal Study and Clinical Correlations | Giulia Midena
9.45 – 10.00 | Assessment of BAP1, PRAME, and CD163 Expression in Relation to Other Tumor Parameters in Uveal Melanoma: A Morphological and Immunohistochemical Study | Michał Jerzy Dopierała
10.00 – 10.05 | Chromosome 8q amplification in the development of UM metastases | Marianna Ambrosio
10.05 – 10.10 | Unusual Ciliochoroidal Tumors | Min Kim
10.10 – 10.15 | Unveiling ocular involvement in leukemia relapse: the crucial role of B-scan ultrasound-A case report | Elvia Mastrogiuseppe
10.15 – 10.20 | Bilateral intraocular involvement of EBV-positive extranodal NK/(T)-cell lymphoma | Alexandra Steinemann
11.00 – 11.15 | Real-World Outcomes of Tebentafusp in Metastatic Uveal Melanoma (UM) patients: A Retrospective Cohort Study at Institut Curie | Raphaël Sanchez
11.15 – 11.30 | Impact of Treatment Delays on Survival in Uveal Melanoma: Expanded Cohort and Analytical Approaches | Anna Hagström
11.30 – 11.45 | Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma | Lennart J. Pors
11.45 – 12.00 | Comparative study of ruthenium-106 brachytherapy versus fractionated stereotactic radiotherapy for uveal melanoma | Mike Wu
12.00 – 12.15 | Radiation retinopathy: morpho-functional outcomes after intravitreal treatment with antivegf and slow-release dexamethasone implant | Maria Grazia Sammarco
12.15 – 12.30 | Ruthenium-106 Brachytherapy and Central Uveal Melanoma | Luise Grajewski
12.30 – 12.45 | OOG collaborative study on extraocular extension of uveal melanoma – results of historical cohort | Iwona Rospond-Kubiak
12.45 – 13.00 | International Validation of an Improved Classification for Ciliary Body and Choroidal Melanomas Based on Estimation of Tumor Volume | Gustav Stålhammar
14.45 – 15.00 | Computer Aided Diagnosis of Eyelid skin tumors Using Machine Learning: Application on Images of Eyelid Skin Lesions | Vicktoria Vishnevskia-Dai
15.00 – 15.15 | Mohs micrographic surgery in periocular tumours: a comparison between two decades | Natasha van Poppelen
15.15 – 15.30 | Impact of clinical, histopathological and molecular biomarkers on local and systemic recurrence in patients with conjunctival melanoma | Monica Maria Pagliara
15.30 – 15.45 | Retrospective analysis of a case series of conjunctival melanoma in a national reference center | López-Miñarro I
15.45 – 16.00 | The Epidemiology of Conjunctival Melanoma in Sweden: A National Cohort Study on Incidence and Trends | Marco A. Lumia Michalski
16.00 | Coffee break
16.30 – 16.45 | Tumor biopsy as prognostic tool for uveal melanoma patients | Paulina Bartoszek
16.45 – 17.00 | Vision Preservation in Juxta-Foveal Uveal Melanoma After Proton Therapy | Johannes Gollrad
17.00 – 17.15 | Reirradiation of recurrent uveal melanoma following prior proton therapy: clinical efficacy and toxicity outcomes | Ann Schalenbourg
17.15 – 17.30 | Prospective analysis of peripapillary microvasculature with spectral domain optical coherence tomography angiography in patients affected by choroidal melanoma | Francesco Baldo Lanza
17.30 – 17.45 | Long-term clinical outcomes of medium-sized uveal melanomas under observation: a retrospective study | Laura Prieto Dominguez
17.45 – 18.00 | Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma | Matthew O’Riordan
RETINOBLASTOMA AND ORBITAL DAY
9.00 – 9.15 | Neovascular Glaucoma as a Predictor of Retinoblastoma High-Risk Histopathology in an International Multicentre Study | Guy Negretti
9.15 – 9.30 | A retrospective study on adjuvant chemotherapy in retinoblastoma: validation of the new recommendation against treatment for pT2a tumors based on the 8th AJCC | Hind M. Alkatan
9.30 – 9.45 | The AMCC program in sub-Saharan Africa to improve the management of retinoblastoma | Denis Malaise
9.45 – 10.00 | Impact of High-Risk Histopathological Features on Outcomes in Unilateral Retinoblastoma: Massive Choroidal Invasion, Retrolaminar Optic Nerve Invasion | Shahar Frenkel
10.00 – 10.15 | Sequencing of RB1 in previously untested survivors of retinoblastoma | Tero T. Kivelä
10.15 – 10.20 | Adjuvant high dose intravitreal topotecan in the management of macular retinoblastoma in a 2-month-old | Dan Gombos
10.20 – 10.25 | Recurrent ciliochoroidal retinoblastoma in a 9-year-old with 13q deletion | Dan Gombos
10.25 – 10.30 | Black Posterior Vitreous Detachment: An 8-year Historical Cohort | Vicktoria Vishnevskia-Dai
11.00 – 11.15 | Rare Paediatric Orbital Tumors | Daniel Briscoe
11.15 – 11.30 | Survival in Merkel Cell Carcinoma | Guy Missotten
11.30 – 11.45 | Neoadjuvant systemic treatment for locally advanced conjunctival melanoma | Martina Angi
11.45 – 12.00 | Fine Needle Aspiration Biopsy and Flow Cytometry in Orbital non-Hodgkin Lymphomas | Raffaele Parrozzani
12.00 – 12.15 | Long-term outcomes after multidisciplinary treatment for pediatric orbital rhabdomyosarcoma | Nur Khatib
12.15 – 12.30 | Topical 5-Fluorouracil 1% in the management of ocular surface squamous neoplasia | Jessica Sergenti
12.30 – 12.35 | A rare case of lacrimal gland adenoid cystic carcinoma | Maria Olteanu
12.35 – 12.40 | Palpebral and conjunctival sebaceous carcinomas, a challenging diagnosis: about 3 cases | Laura Ninet
12.40 – 12.45 | Conservative treatment of conjunctival dedifferentiated liposarcoma | Alice Carra
12.45 – 12.50 | Case Presentation – Management of Benign Fibrous Histiocytoma of the Conjunctiva | Peter Skov Jensen
12.50 – 12.55 | Rapidly Progressing Proptosis and Vision Loss in an 84-Year Old: A Diagnostic Challenge | Yamini Krishna
12.55 – 13.00 | Iris extension of an invasive conjunctival squamous cell carcinoma treated by proton beam therapy: a case report | Solène Kairis
14.45 – 15.00 | Optic pathway Glioma in pediatric patients treated with MEK inhibitors and standard chemotherapy: visual, tomographic, and clinical outcomes | Federico Carlucci
15.00 – 15.15 | Epidemiology, diagnosis, and outcomes of ocular (choroidal and orbital) metastases: retrospective cohort study from a tertiary center | Arad Dotan
15.15 – 15.30 | Prognostic value of BAP1 and PRAME immunohistochemistry in iris melanoma | Mette Marie Bagger Sjøl
15.45 – 16.00 | Prevalence and Characteristics of Choroidal Nevi in 34,793 individuals. A nation-wide study based on optician fundus photography | Carsten Faber
16.30 – 16.45 | Role of aspirin in preventing carboplatin induced vascular thrombosis following intra-arterial chemotherapy (IAC) | Dan Gombos
16.45 – 17.00 | Evidence of inflammatory mechanisms in an animal model of radiation retinopathy | Alexandre Matet
17.00 – 17.05 | Diffuse fundus hypopigmentation associated with immunotherapy for metastatic melanoma | Jørgen Krohn
17.05 – 17.10 | Anterior chamber infiltration of CAR T-cells | Vicktoria Vishnevskia-Dai
17:10-17:15 | Rare tumors and endless stories | Doris Hadjistilianou
17:15-17:20 | PVF associated with…? | Doris Hadjistilianou
17:20-17:30 l Uveal melanoma management, the role of multidisciplinary ocular and periocular cancer meetings over a 2-year period | Federico Giannuzzi